Avtor/Urednik     Lavrenčič, Aleša
Naslov     Irbesartan za zdravljenje arterijske hipertenzije
Prevedeni naslov     Irbesartan in the treatment of arterial hypertension
Tip     članek
Vir     In: Hojs R, Krajnc I, Pahor A, editors. Zbornik predavanj in praktikum 11. srečanje internistov in zdravnikov splošne medicine Iz prakse za prakso z mednarodno udeležbo; 2000 maj 19-20; Maribor. Maribor: Splošna bolnišnica Maribor,
Leto izdaje     2000
Obseg     str. 249-62
Jezik     slo
Abstrakt     This article reviews the pharmacokinetics, pharmacodynamics, efficacy and safety of irbesartan, a new antihypertensive agent from the group of angiotensin II receptor antagonists. Irbesartan inhibits the renin-angiotensin system by selectively blocking the AT, subtype of angiotensin II receptors. It has the highest oral bioavailability (60 to 80%) and the longest elimination half-life (11 to 15 h) in its class. It exhibits the lowest amount of protein binding. The pharmacokinetics of irbesartan are not altered in renally or hepatically impaired patients. Irbesartan lowers blood pressure in a dose- related manner at doses up to 300 mg daily. Once daily dosing provides full 24 h blood pressure control. Irbesartan achieves excellent long-term control of blood pressure in patients with mild-to-moderate hypertension. The antihypertensive effect of irbesartan is comparable to or exceeds that of leading antihypertensive agents. Whereas irbesartan demonstrates a relationship between dose and antihypertensive effect, there is no such relationship between dose and rates of adverse events, the incidence of which is comparable to that in placebo. Thus, irbesartan provides significant dose- related antihypertensive effects with placebo-like tolerability, thereby expanding the therapeutic window in the treatment of hypertension.
Deskriptorji     HYPERTENSION
ANGIOTENSIN II
RECEPTORS, ANGIOTENSIN